progenics pharmaceuticals inc. Resources | BNET
On The Insider: Sexiest Magazine Covers of All Time

BNET Industries

Progenics Pharmaceuticals Inc. (PGNX) is in the Pharma Industry

Revenue
Dec 31 2007
$75.6M
Profit
Dec 31 2007
($43.6M)
Market Cap
Oct 03 2008
$391.3M

Latest News and Analysis

  • Research and Markets: New PEST and SWOT Analysis of Progenics Pharmaceuticals

    DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c93813) has announced the addition of "Analysis of Progenics Pharmaceuticals" to their offering. We present Analysis of Progenics Pharmaceuticals. A complete and comprehensive analysis of Progenics Pharmaceuticals, includes an overview of the industry the company operates in, a PEST...

    Articles 2008-06-05

  • Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations

    COLLEGEVILLE, Pa. & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR([TM]) methylnaltrexone bromide. The first of these studies, a phase 2 trial,...

    Articles 2008-05-22

  • Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047

    BRISBANE, Australia, May 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047) for patients with advanced cancer. Progen has commenced development of PG-11047 - the...

    Articles 2008-05-15

  • Progenics Pharmaceuticals Reports First Quarter 2008 Results

    TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2008. Revenues for the quarter totaled $14.8 million compared to revenues of $17.6 million for the same period in 2007. Revenues primarily reflect reimbursement by the Company's collaborator,...

    Articles 2008-05-09

  • Wall Street News Alert: UDTT Is on the Move! April 28, 2008

    Wall Street News Alert's "stocks to watch" thismorning are: Universal Detection Technology (OTCBB: UDTT), GE (NYSE: GE),Tyco International Ltd. (NYSE: TYC) and Progenics Pharmaceuticals, Inc.(NASDAQ: PGNX). Having announced it has received a purchase order from an Israeli companyfor the Company's Hand Held Assays, Universal Detection Technology (OTCBB: UDTT) should continue...

    Articles 2008-04-28

  • Progenics and Wyeth Announce FDA Has Approved RELISTOR

    First Drug for Opioid-Induced Constipation to Launch in United States TARRYTOWN, N.Y. & COLLEGEVILLE, Pa. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration FDA has approved RELISTOR[TM] methylnaltrexone bromide subcutaneous injection for...

    Articles 2008-04-25

  • Progenics Pharmaceuticals to Host Conference Call Tomorrow at 10:00 AM Eastern Time to Discuss the Approval of RELISTOR

    TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) will hold a conference call tomorrow at 10:00 AM Eastern Time to discuss the U.S. Food and Drug Administration's approval of RELISTORTM methylnaltrexone bromide for subcutaneous injection. RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness receiving...

    Articles 2008-04-25

  • Progenics and Wyeth Announce FDA Has Approved RELISTOR

    First Drug for Opioid-Induced Constipation to Launch in United States TARRYTOWN, N.Y. & COLLEGEVILLE, Pa. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration FDA has approved RELISTOR[TM] methylnaltrexone bromide subcutaneous injection for...

    Articles 2008-04-24

  • BellwetherReport.com Initiates Analyst Coverage on PGNX, AMR, MBI and MU

    BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of...

    Articles 2008-04-24

  • Progenics Board Approves $15 Million Share Repurchase Program

    TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its Board of Directors has approved a share repurchase program to acquire up to $15 million of its outstanding common shares. Funding for the repurchase program will come from the $15 million milestone payment Progenics will receive...

    Articles 2008-04-24

  • BenchmarkJournal.com Small-Cap Sector Analysis for KNDI, IRSN, PGNX and NXTM

    Benchmark Journal brings independent company andsector research together, utilizing top financial advisors and investmenttactics to provide you with a clear picture of investment opportunities.Once you register as a free member to www.benchmarkjournal.com , you will begranted full access to our site, including sector analysis and companyanalysis. Our company profiles...

    Articles 2008-04-01

  • Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval

    First-in-world approval of drug to treat opioid induced constipation COLLEGEVILLE, Pa. & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that Wyeth has received marketing approval from Health Canada, the Canadian Regulatory Agency, for RELISTOR[TM] (methylnaltrexone bromide...

    Articles 2008-04-01

  • MIDD, MTEX, PFCB, PGNX, UBFO, YRCW Have Also Been Added To Naked Short List Today.

    M2 PRESSWIRE-31 March 2008-BUYINS.NET: MIDD, MTEX, PFCB, PGNX, UBFO, YRCW Have Also Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:31032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and...

    Articles 2008-03-31

  • Progenics Pharmaceuticals Reports Fourth Quarter and Year End Results

    TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2007. Revenues for the fourth quarter ended December 31, 2007 totaled $15.5 million compared to $21.9 million for the same quarter in 2006. For the...

    Articles 2008-03-17

  • Free Analytical Report for Progenics Pharmaceutical Inc.

    M2 PRESSWIRE-13 March 2008-Bellwether Interviews: Free Analytical Report for Progenics Pharmaceutical Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:13032008 BellwetherReport.com is always trying to get the edge on the market and have introduced a new service that will consist of interviewing top...

    Articles 2008-03-13

  • page 1 of 1
  • Incorporated: 1986
  • CEO: Dr. Paul J. Maddon M.D., Ph
  • Employees: 245

Progenics Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic products to treat the medical needs of patients with debilitating conditions and life-threatening diseases. Co.'s principal programs are directed toward three areas, which include: gastroenterology, where Co. is focusing on methylnaltrexone for treating opioid-induced constipation and management of post-operative ileus; virology, where Co. is developing viral-entry inhibitors, which are molecules designed to inhibit the ability of viruses to enter certain types of immune system cells; and oncology, where Co. is developing immunotherapies for prostate cancer.

Key Competitors

advertisement
Progenics Pharmaceuticals Inc. Company Info

Board of Directors

Mr. Kurt W. Briner

Co-Chairman

Mr. Paul F. Jacobson

Co-Chairman

Dr. Paul J. Maddon M.D., Ph

Mr. Charles A. Baker

Mr. Mark F. Dalton

Dr. Stephen P. Goff Ph.D.

Dr. David A. Scheinberg M.D., Ph

Ms. Nicole S. Williams

Contact Information

777 Old Saw Mill River Road

Tarrytown, NY

http://www.progenics.com

914 789-2800

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement